Barclays Says No Short Term Fix For Valeant

Shares of the troubled Canadian drug company fell as much as five percent Thursday following a bearish note from an analyst team at Barclays. The analysts said they see 'no short term fix' for Valeant (VRX) getting itself out of trouble. Real Money's James Passeri reported Thursday that Valeant is 'up against a wall' and must sell assets in order to tackle its $31 billion debt load. Failure to meet its EBITDA targets could mean that Valeant would breach the covenants on some of its debt. Read Passeri's report on Real Money to find out more.

This article was written by a staff member of TheStreet.